Grisanti Capital Management Has Boosted Celgene (CELG) Holding; CareDx Has 6.14 Sentiment

March 24, 2018 - By Hazel Jackson

Grisanti Capital Management Llc increased Celgene Corp (CELG) stake by 43.77% reported in 2017Q3 SEC filing. Grisanti Capital Management Llc acquired 12,188 shares as Celgene Corp (CELG)’s stock declined 3.49%. The Grisanti Capital Management Llc holds 40,032 shares with $5.84M value, up from 27,844 last quarter. Celgene Corp now has $63.92B valuation. The stock decreased 2.22% or $1.93 during the last trading session, reaching $84.98. About 7.23M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since March 24, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $215.10 million. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

Since September 25, 2017, it had 1 buy, and 3 selling transactions for $3.58 million activity. Shares for $299,594 were bought by Alles Mark J on Thursday, February 8. 13,370 shares were sold by MARIO ERNEST, worth $1.26 million on Friday, February 23. $248,498 worth of Celgene Corporation (NASDAQ:CELG) was sold by Curran Terrie on Monday, September 25. The insider LOUGHLIN JAMES J sold $851,093. 18,500 shares were sold by KAPLAN GILLA, worth $1.77 million.

Investors sentiment decreased to 0.83 in 2017 Q3. Its down 0.34, from 1.17 in 2017Q2. It is negative, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Private Wealth Prtn holds 112,249 shares or 3.29% of its portfolio. Philadelphia Trust Co has 149,711 shares. Novare Capital Mgmt Ltd Liability Com owns 48,779 shares for 1.25% of their portfolio. Wedgewood Partners invested in 676,776 shares or 3.37% of the stock. Thompson Siegel & Walmsley Ltd Liability Corporation accumulated 2,219 shares. 85,987 were accumulated by Bokf Na. Comerica Bancorp has invested 0.18% of its portfolio in Celgene Corporation (NASDAQ:CELG). Crestpoint Capital Mngmt Ltd Liability Corp has invested 0.33% of its portfolio in Celgene Corporation (NASDAQ:CELG). Gamco Invsts Et Al accumulated 10,250 shares or 0.01% of the stock. S&Co reported 12,723 shares. Tru Of Oklahoma invested 1.6% in Celgene Corporation (NASDAQ:CELG). Fayez Sarofim And Company holds 611,672 shares. Renaissance Gru Limited Liability Corporation holds 1.25% or 248,722 shares. San Francisco Sentry Inv Gp (Ca) holds 17,089 shares. The Massachusetts-based Anchor Capital Ltd Liability Co has invested 0.01% in Celgene Corporation (NASDAQ:CELG).

Among 34 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 2 Sell and 13 Hold. Therefore 56% are positive. Celgene Corporation had 139 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Sunday, August 13. The stock has “Buy” rating by Credit Suisse on Monday, October 30. JMP Securities maintained Celgene Corporation (NASDAQ:CELG) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $152 target. The firm has “Hold” rating by Wells Fargo given on Thursday, October 26. The company was maintained on Thursday, July 6 by Credit Suisse. Credit Suisse maintained Celgene Corporation (NASDAQ:CELG) rating on Monday, January 8. Credit Suisse has “Buy” rating and $125.0 target. Raymond James initiated the shares of CELG in report on Tuesday, September 1 with “Strong-Buy” rating. Oppenheimer maintained the shares of CELG in report on Wednesday, June 14 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 8 report. The firm has “Buy” rating given on Friday, October 20 by SunTrust.

The stock increased 25.75% or $1.54 during the last trading session, reaching $7.52. About 4.10M shares traded or 1325.74% up from the average. CareDx, Inc (CDNA) has declined 74.10% since March 24, 2017 and is downtrending. It has underperformed by 90.80% the S&P500.

Paragon Associates & Paragon Associates Ii Joint Venture holds 4.02% of its portfolio in CareDx, Inc for 1.27 million shares. Gagnon Securities Llc owns 2.17 million shares or 2.87% of their US portfolio. Moreover, Gagnon Advisors Llc has 2.68% invested in the company for 3,536 shares. The Virginia-based Thompson Davis & Co. Inc. has invested 1.33% in the stock. Perkins Capital Management Inc, a Minnesota-based fund reported 138,550 shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: